Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDKTYU)

• Drug Name: Anti-EGFRvIII CAR transduced PBL Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Brain cancer	2A00	Phase 1/2	[1]
Malignant glioma	2A00.0	Phase 1/2	[1]
Recurrent glioblastoma	2A00.00	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMDKTYU

Molecule-Related Drug Atlas

Drug(s) Targeting Epidermal growth factor receptor variant III (EGFR vIII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EGFRvIII CAR	DMC284G	Glioblastoma multiforme	2A00.0	Phase 1/2	[2]
Anti-EGFR V III CAR-T cells	DM8EAGV	Glioma	2A00.0	Phase 1/2	[3]
AMG 596	DM4G1SP	Glioblastoma multiforme	2A00.0	Phase 1	[4]
D2C7	DMIMK84	Glioblastoma of brain	2A00.00	Phase 1	[5]
EGFRvIII CAR T cells	DM6XWV4	Glioblastoma multiforme	2A00.0	Phase 1	[6]
CAR-T cells targeting EGFRviii	DMRSG04	Glioblastoma multiforme	2A00.0	Phase 1	[7]
Anti-EGFRvIII CAR T cells	DM73920	Glioblastoma multiforme	2A00.0	Phase 1	[8]
CART-EGFRvIII T cells	DMGPR1C	Recurrent glioblastoma	2A00.00	Phase 1	[9]
EGFRvIII-CARs	DMA46RN	Recurrent glioblastoma	2A00.00	Phase 1	[10]
CAR-T cells targeting EGFRviii	DMRSG04	Glioblastoma multiforme	2A00.0	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor variant III (EGFR vIII)	TTZ6B2I	EGFR_HUMAN	CAR-T-Cell-Therapy	[1]

References

• [1] ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
• [2] EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84.
• [3] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [4] Clinical pipeline report, company report or official report of Amgen.
• [5] Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
• [6] ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
• [7] ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
• [8] ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
• [9] ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
• [10] ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
• [11] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.